Lead Product(s): Fondaparinux
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Arixtra
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Mylan Inc.
Deal Size: $757.2 million Upfront Cash: $310.4 million
Deal Type: Acquisition September 08, 2020
Under the terms of the agreement, Mylan Ireland Limited will acquire the commercialisation rights and related intellectual property relating to Aspen’s Thrombosis Business in Europe which includes Arixtra, Fraxiparine, Mono-Embolex and Orgaran.